Demographic characteristics of patients with APS grouped by anti-β2GPI-DI IgG positivity and control patients with SLE
| APS (n=169) | Anti-β2GPI-DI IgG-positive APS (n=55) | Anti-β2GPI-DI IgG-negative APS (n=114) | SLE without APS (n=209) | |
| Secondary APS | 50 (29.6) | 16 (29.1) | 34 (29.8) | |
| Demographic features | ||||
| Female (n (%)) | 117 (69.2) | 40 (72.7) | 77 (67.5) | 192 (91.9) |
| Age at diagnosis (median, IQR) | 34 (31, 41) | 34 (31, 40) | 35 (31, 42) | 33 (28, 40) |
| BMI (median, IQR) | 23.9 (21.5, 26.4) | 24.4 (22.0, 26.0) | 23.6 (21.4, 26.5) | 22.0 (20.1, 24.5) |
| Conventional risk factor | ||||
| Diabetes mellitus (n (%)) | 6 (3.6) | 2 (3.6) | 4 (3.5) | 1 (0.6) |
| Arterial hypertension (n (%)) | 32 (18.9) | 16 (29.1) | 16 (14.0) | 12 (7.5) |
| Smoking (n (%)) | 32 (18.9) | 5 (9.1) | 27 (23.7) | 12 (7.2) |
| Coronary artery disease (n (%)) | 6 (3.6) | 0 (0.0) | 6 (5.3) | 0 (0.0) |
| Thrombosis (n (%)) | 131 (77.5) | 45 (81.8) | 85 (75.4) | – |
| Venous thrombosis (n (%)) | 81 (47.9) | 26 (47.3) | 55 (48.3) | – |
| Arterial thrombosis (n (%)) | 56 (33.1) | 22 (40.0) | 34 (29.8) | – |
| Venous and arterial thrombosis (n (%)) | 19 (11.2) | 6 (10.9) | 13 (11.4) | – |
| Microvascular thrombosis (n (%)) | 33 (19.5) | 16 (29.1) | 17 (14.9) | – |
| Recurrent thrombosis before diagnosis (n (%)) | 114 (67.5) | 25 (45.5) | 30 (26.3) | – |
| Adverse pregnancy history (n (%)) | 68 (70.1, 97) | 23 (74.2, 31) | 45 (68.2, 66) | – |
| Pre-eclampsia, eclampsia and placental dysfunction (n (%)) | 21 (21.6) | 9 (29.0) | 12 (18.2) | – |
| Early miscarriages ≥1 (n (%)) | 30 (30.9) | 12 (38.7) | 18 (27.3) | – |
| Fetal death (≥10 weeks) (n (%)) | 35 (36.1) | 9 (29.0) | 26 (39.4) | – |
| Extra-criteria manifestations (n (%)) | 86 (50.9) | 38 (69.1) | 48 (42.1) | – |
| Thrombocytopenia (n (%)) | 72 (42.6) | 29 (52.7) | 43 (37.7) | – |
| Autoimmune haemolytic anaemia (n (%)) | 19 (11.2) | 6 (10.9) | 13 (11.4) | – |
| Valvular lesions (n (%)) | 12 (7.1) | 5 (9.1) | 7 (6.1) | – |
| APS nephropathy (n (%)) | 11 (6.5) | 7 (12.7) | 4 (3.5) | – |
| Non-vascular neurological manifestations (n (%)) | 15 (8.9) | 8 (14.6) | 7 (6.1) | – |
Only female patients with at least one conception were included in the analysis of adverse pregnancy history.
Anti-β2GPI-DI, anti-β2GPI-domain I; APS, antiphospholipid syndrome; BMI, body mass index.